CD274 and cervical cancer: In 2017, the KEYNOTE-028 trial first showed the favourable safety and efficacy outcomes of single agent of Pembrolizumab in PD-L1–positive advanced cervical cancer that the median overall survival (mOS) was 11 months with acceptable incidence of severe adverse events (AEs) as 20.8% (16).